Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Incannex Healthcare Inc

IXHL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$3.28

▲ +3.80%

Market Cap $39.24M · Vol 41.96K

Key Metrics

P/E Ratio

N/A

FWD: 3.67

Market Cap

$39.24M

Micro Cap

Div Yield

N/A

EPS Growth

+94.67%

YoY

RSI (14)

74.38

Momentum

Beta

3.07

vs Market

52W High

$27.61

88.12% below

52W Low

$2.49

31.73% above

Volume

41.96K

Avg 30.34K

P/B

3.13

Price-to-book

ROE

N/A

Return on equity

Free Float

87.66%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Incannex Healthcare Inc (IXHL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IXHL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.96%

+3.47%

-15.46%

-59.37%

YTD

-69.46%

-72.32%

-98.29%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$86.00K
Net Income	$-46,885,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-27,661.63%
Net Profit Margin	-54,517.44%
ROE	N/A
ROA · ROIC	-250.09% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	3.67
PEG Ratio	N/A
P/S	86.42
P/B	3.13
P/FCF	N/A
EPS Growth	+94.67%
Outstanding Shares	11.96M

Technical Indicators

50-Day SMA	$3.33
200-Day SMA	$6.44
RSI (14)	74.38
Beta	3.07
52-Week High	$27.61
52-Week Low	$2.49

Volume Today	41.96K
Avg Daily Volume (30D)	30.34K
Relative Volume	1.38x
Volatility (10D)	26.21
Volatility (30D)	47.12
Free Float	87.66%

Analyst Consensus

BUY

Current Price $3.28

Mean Target $18.00

52W Low$2.49 52W High$27.61

Current

Target

$2.49 $27.61

Current Analyst target

+448.78% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01J0814Z1

ISINUS45333F2083

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateSep 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.